>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

Roxadustat 罗沙司他; FG-4592

Roxadustat (FG-4592) 是一种口服低氧诱导因子脯氨酰羟化酶抑制剂 (HIF-PHI)，通过增加内源性促红细胞生成素、改善铁调节和降低铁调素来促进红细胞生成。

货号：
TK0547
规格：

2mg

5mg

10mg

50mg

100mg
价格：
￥0.00

产品参数

CAS No.	808118-40-3
生物活性	Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin.
分子式	C19H16N2O5
分子量	352.34
运输条件	Room temperature in continental US; may vary elsewhere.
储存条件	Powder -20°C 3 years
溶解性数据	DMSO : 100 mg/mL (283.82 mM) H2O : < 0.1 mg/mL (ultrasonic) (insoluble)
体内研究	Roxadustat (50 mg/kg; i.p.; daily for 7 days) protects the survival of motor neurons and improves recovery from spinal cord injury.
体外研究	Roxadustat (5-50 μM; 6 hours) significantly inhibits TBHP-induced apoptosis in PC12 cells. Roxadustat (50 μM; 6 hours) stabilizes HIF-1α protein expression in PC12 cells.
文献	•Science. 2016 Apr 1;352(6281):54-61. •Cell Metab. 2019 Nov 5;30(5):937-951.e5. •Cell Metab. 2017 Jan 10;25(1):73-85. •Mol Cell. 2021 May 6;81(9):2041-2052.e6. •Autophagy. 2020 Dec 19;1-16. •Cell Rep. 2021 Aug 24;36(8):109607. •EMBO Rep. 2021 Nov 15;e53054. •J Biomed Sci. 2021 Nov 2;28(1):73. •Front Cell Dev Biol. 2021 Jul. •J Cell Mol Med. 2019 Jan;23(1):349-356. •J Biol Chem. 2021 Feb 8;100397. •Nanomaterials. 2022 Jan 3;12(1):163. •J Pharmaceut Biomed. 2020, 113870. •Drug Test Anal. 2021 Feb 10. •Drug Test Anal. 2020 Aug 27. •Circ J. 2020 May 25;84(6):1028-1033. •Biomed Chromatogr. 2021 Feb;35(2):e4970. •Patent. US20180263995A1.
纯度及产品资料	98%

推荐产品